These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction. Groutz A; Amit A; Yaron Y; Yovel I; Wolman I; Legum C; Lessing JB Prenat Diagn; 1996 Aug; 16(8):723-7. PubMed ID: 8878282 [TBL] [Abstract][Full Text] [Related]
4. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies. Benn PA Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476 [TBL] [Abstract][Full Text] [Related]
5. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. Wald N; Cuckle H; Wu TS; George L Br J Obstet Gynaecol; 1991 Sep; 98(9):905-8. PubMed ID: 1716981 [TBL] [Abstract][Full Text] [Related]
6. Second-trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies. Rice JD; McIntosh SF; Halstead AC Prenat Diagn; 2005 Mar; 25(3):234-8. PubMed ID: 15791658 [TBL] [Abstract][Full Text] [Related]
7. Maternal serum analyte levels after first-trimester multifetal pregnancy reduction. Shulman LP; Phillips OP; Cervetti TA Am J Obstet Gynecol; 1996 Mar; 174(3):1072-4. PubMed ID: 8633639 [TBL] [Abstract][Full Text] [Related]
8. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes]. Hu Z; Liu X; Li L; Jia C; Li D; Liu R Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246 [TBL] [Abstract][Full Text] [Related]
9. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701 [TBL] [Abstract][Full Text] [Related]
10. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome. Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657 [TBL] [Abstract][Full Text] [Related]
11. The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down's syndrome. Kim SY; Kim SK; Lee JS; Kim IK; Lee K Yonsei Med J; 2000 Apr; 41(2):226-9. PubMed ID: 10817024 [TBL] [Abstract][Full Text] [Related]
12. Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Lepage N; Chitayat D; Kingdom J; Huang T Am J Obstet Gynecol; 2003 May; 188(5):1354-9. PubMed ID: 12748511 [TBL] [Abstract][Full Text] [Related]
13. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome. Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623 [TBL] [Abstract][Full Text] [Related]
16. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns. Sayin NC; Canda MT; Ahmet N; Arda S; Süt N; Varol FG Arch Gynecol Obstet; 2008 Jan; 277(1):47-53. PubMed ID: 17653738 [TBL] [Abstract][Full Text] [Related]
17. Maternal midtrimester serum AFP and free beta-hCG levels in in vitro fertilization twin pregnancies. Räty R; Virtanen A; Koskinen P; Laitinen P; Forsström J; Salonen R; Mörsky P; Ekblad U Prenat Diagn; 2000 Mar; 20(3):221-3. PubMed ID: 10719325 [TBL] [Abstract][Full Text] [Related]
18. Risk of abnormal triple screen for Down syndrome is significantly higher in patients with female fetuses. Spong CY; Ghidini A; Stanley-Christian H; Meck JM; Seydel FD; Pezzullo JC Prenat Diagn; 1999 Apr; 19(4):337-9. PubMed ID: 10327139 [TBL] [Abstract][Full Text] [Related]
19. Outcome validation of the Beckman Coulter access analyzer in a second-trimester Down syndrome serum screening application. MacRae AR; Gardner HA; Allen LC; Tokmakejian S; Lepage N Clin Chem; 2003 Jan; 49(1):69-76. PubMed ID: 12507962 [TBL] [Abstract][Full Text] [Related]